Zhaohui Su

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211
    Zhaohui Su
    Harvard School of Public Health, Boston, Massachusetts 02115, USA
    J Infect Dis 200:1724-8. 2009
  2. ncbi Vicriviroc resistance decay and relative replicative fitness in HIV-1 clinical isolates under sequential drug selection pressures
    Athe M N Tsibris
    Brigham and Women s Hospital, Boston, Massachusetts, USA
    J Virol 86:6416-26. 2012
  3. ncbi Assessing human immunodeficiency virus type 1 tropism: Comparison of assays using replication-competent virus versus plasma-derived pseudotyped virions
    Noriaki Hosoya
    Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    J Clin Microbiol 47:2604-6. 2009
  4. ncbi Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: results of the AIDS Clinical Trials Group A5211
    Athe M N Tsibris
    Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Clin Infect Dis 48:642-9. 2009
  5. ncbi In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject
    Athe M N Tsibris
    Massachusetts General Hospital, Boston, Massachusetts, USA
    J Virol 82:8210-4. 2008
  6. ncbi Incidence and patterns of polydrug use and craving for ecstasy in regular ecstasy users: an ecological momentary assessment study
    James W Hopper
    Behavioral Psychopharmacology Research Laboratory, Department of Psychiatry, Harvard Medical School and McLean Hospital, Belmont, MA 02478, USA
    Drug Alcohol Depend 85:221-35. 2006
  7. ncbi Benztropine pretreatment does not affect responses to acute cocaine administration in human volunteers
    David M Penetar
    Behavioral Psychopharmacology Research Laboratory, McLean Hospital Harvard Medical School MA 02478, USA
    Hum Psychopharmacol 21:549-59. 2006
  8. ncbi Association of HIV neutralizing antibody with lower viral load after treatment interruption in a prospective trial (A5170)
    Robert J McLinden
    University of Hawai i at Manoa, Honolulu, Hawaii, USA
    AIDS 26:1-9. 2012

Detail Information

Publications8

  1. ncbi Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211
    Zhaohui Su
    Harvard School of Public Health, Boston, Massachusetts 02115, USA
    J Infect Dis 200:1724-8. 2009
    ..91 versus -0.57 log(10) copies/mL at week 24, respectively. Results suggest that the enhanced-sensitivity assay is a better screening tool for determining patient eligibility for CCR5 antagonist therapy...
  2. ncbi Vicriviroc resistance decay and relative replicative fitness in HIV-1 clinical isolates under sequential drug selection pressures
    Athe M N Tsibris
    Brigham and Women s Hospital, Boston, Massachusetts, USA
    J Virol 86:6416-26. 2012
    ..These findings suggest that while VCV and enfuvirtide select for resistance mutations in only one env subunit, gp120 and gp41 coevolve to maximize viral fitness under sequential drug selection pressures...
  3. ncbi Assessing human immunodeficiency virus type 1 tropism: Comparison of assays using replication-competent virus versus plasma-derived pseudotyped virions
    Noriaki Hosoya
    Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    J Clin Microbiol 47:2604-6. 2009
    ..Concordance with the Trofile assay was good, but assays using replicating viruses did not increase substantially the ability to detect the presence of CXCR4-using virus...
  4. ncbi Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: results of the AIDS Clinical Trials Group A5211
    Athe M N Tsibris
    Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Clin Infect Dis 48:642-9. 2009
    ....
  5. ncbi In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject
    Athe M N Tsibris
    Massachusetts General Hospital, Boston, Massachusetts, USA
    J Virol 82:8210-4. 2008
    ..Pretreatment V3 loop sequences reemerged following VCV discontinuation, implying that VCV resistance has associated fitness costs...
  6. ncbi Incidence and patterns of polydrug use and craving for ecstasy in regular ecstasy users: an ecological momentary assessment study
    James W Hopper
    Behavioral Psychopharmacology Research Laboratory, Department of Psychiatry, Harvard Medical School and McLean Hospital, Belmont, MA 02478, USA
    Drug Alcohol Depend 85:221-35. 2006
    ..Previous studies employing retrospective assessments methods found that regular ecstasy users frequently use alcohol, marihuana and other drugs in combination with ecstasy...
  7. ncbi Benztropine pretreatment does not affect responses to acute cocaine administration in human volunteers
    David M Penetar
    Behavioral Psychopharmacology Research Laboratory, McLean Hospital Harvard Medical School MA 02478, USA
    Hum Psychopharmacol 21:549-59. 2006
    ..The exact therapeutic application of benztropine as a possible adjunct treatment for cocaine abuse in humans require further exploration...
  8. ncbi Association of HIV neutralizing antibody with lower viral load after treatment interruption in a prospective trial (A5170)
    Robert J McLinden
    University of Hawai i at Manoa, Honolulu, Hawaii, USA
    AIDS 26:1-9. 2012
    ..We investigated the impact of neutralizing antibodies (NAbs) on CD4 T-cell count and viral load in a cohort of HAART recipients who underwent extended structured treatment interruption...